Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 118 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ATM Clear all
Recruiting No phase listed Observational

ExoLuminate Study for Early Detection of Pancreatic Cancer

NCT05625529
View directory record Official record
Conditions
Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
Biological Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 5, 2026, 1:13 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

NCT05396833
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
Tuvusertib, Lartesertib, Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Santa Rosa, California • Miami, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 5, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

M6620 (VX-970) in Selected Solid Tumors

NCT03718091
View directory record Official record
Conditions
Solid Tumor, Leiomyosarcoma, Osteosarcoma
Interventions
M6620
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 5, 2026, 1:13 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pilot Study of Pancreatic Cancer Screening

NCT05058846
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Biospecimen Collection, Magnetic Resonance Cholangiopancreatography, Magnetic Resonance Imaging, Endoscopic ultrasound, Questionnaires
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 5, 2026, 1:13 AM EDT
Not yet recruiting Not applicable Interventional

Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation

NCT01952873
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Stent Occlusion
Interventions
Prolonged inflation, Rapid inflation
Other
Lead sponsor
Central Arkansas Veterans Healthcare System
Federal
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 5, 2026, 1:13 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00560495
View directory record Official record
Conditions
Lung Cancer
Interventions
ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis, Tc 99m sestamibi, radiation therapy
Drug · Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Sep 5, 2026, 1:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

NCT05566574
View directory record Official record
Conditions
Solid Tumor, Metastatic Cancer
Interventions
RP-3500, External Beam Radiotherapy (EBRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 5, 2026, 1:13 AM EDT
Terminated Phase 2 Interventional Results available

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

NCT03565991
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1
Interventions
Avelumab, Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
72
States / cities
Palo Alto, California • Stanford, California • Alpharetta, Georgia + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 5, 2026, 1:13 AM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 5, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

NCT01738191
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
35 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 5, 2026, 1:13 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of ATN-224 in Patients With Prostate Cancer

NCT00405574
View directory record Official record
Conditions
Prostate Cancer
Interventions
ATN-224
Drug
Lead sponsor
Attenuon
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Sep 5, 2026, 1:13 AM EDT
Recruiting No phase listed Observational

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

NCT03250078
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
MRI/MRCP
Diagnostic Test
Lead sponsor
Nuvance Health
Other
Eligibility
50 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 5, 2026, 1:13 AM EDT
Completed No phase listed Observational

Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01005368
View directory record Official record
Conditions
Leukemia
Interventions
fluorescence in situ hybridization, mutation analysis, nucleic acid sequencing, polymerase chain reaction, western blotting, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
35
States / cities
San Diego, California • Lewes, Delaware • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 5, 2026, 1:13 AM EDT
Active, not recruiting Phase 2 Interventional

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845
View directory record Official record
Conditions
Solid Tumors
Interventions
Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
32
States / cities
Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 5, 2026, 1:13 AM EDT
Active, not recruiting Phase 2 Interventional

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

NCT03682289
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Ceralasertib, Olaparib, Durvalumab
Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Duarte, California • San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 5, 2026, 1:13 AM EDT
Completed Phase 1 Interventional

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

NCT03188965
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Elimusertib (BAY1895344)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
14
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 5, 2026, 1:13 AM EDT
Completed Not applicable Interventional Results available

Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery

NCT04784637
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Web Simulation Tool (WST), Behavioral Adaptation Module (BAM), Auto Titration Module (ATM), Automated Insulin Delivery (AID) System
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 5, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

NCT04768296
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Berzosertib, Topotecan
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Santa Rosa, California • Topeka, Kansas • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 5, 2026, 1:13 AM EDT
Active, not recruiting Phase 1 Interventional

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

NCT04170153
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
M1774, Niraparib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Austin, Texas • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 1:13 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

NCT00352742
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ATN-224 + bortezomib
Drug
Lead sponsor
Attenuon
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Fresno, California • West Hollywood, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2008 · Synced Sep 5, 2026, 1:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

NCT06134375
View directory record Official record
Conditions
Triple Negative Breast Cancer, Residual Disease
Interventions
Tetrathiomolybdate, Capecitabine, Pembrolizumab
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
3
States / cities
Indianapolis, Indiana • Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 5, 2026, 1:13 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

NCT03403205
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, SoC Therapy
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 5, 2026, 1:13 AM EDT
Completed Phase 2 Interventional

Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI)

NCT01220713
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post-Concussive Syndrome
Interventions
Hyperbaric Oxygen Therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
19 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Portsmouth, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Sep 5, 2026, 1:13 AM EDT
Completed Phase 1 Interventional Results available

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

NCT04882917
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
M4076
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 5, 2026, 1:13 AM EDT